GLPwatch
[GLP-1 receptor activation effects the p38MAPK signal pathway in hepatic stellate cells].
Zhonghua Gan Zang Bing Za Zhi · 2015
Last updated 2026-05-28In a lab study, researchers found that activating GLP-1 receptors in liver cells reduced activity in a specific signaling pathway called p38MAPK. After 120 hours of treatment with the GLP-1 drug liraglutide, levels of p38MAPK activity dropped significantly compared to untreated cells.
AI summary of the abstract below.
| Journal | Zhonghua Gan Zang Bing Za Zhi, 2015 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Mash |
Abstract
OBJECTIVE: To investigate the effects of activation of the GLP-1 receptor on the p38MAPK signaling pathway in hepatic stellate cells (HSCs).
METHODS: HSCs were isolated and identified according to morphological features; the levels of GLP-1R protein were determined by western blotting.The HSCs were randomly divided into a control grouP (normal saline treatment) and experimental grouP(liraglutide treatment); after 120 hours, the expression of p38MAPK mRNA was examined by RT-PCR and of phosphorylated (p)-p38MAPK protein was detected by western blotting.
RESULTS: GLP-1R proteins were detected in the HSCs. Compared with the control group, the experimental group showed significantly decreased p38MAPK mRNA and p-p38MAPK protein (both P < 0.01).
CONCLUSION: The p38MAPK signaling pathway could be down-regulated when GLP-1R is activated in HSCs.
Verbatim abstract via PubMed 25880980 ↗